Merck's ENFLONSIA Approval Adds RSV Defense but Leaves Keytruda Transition Risks Unchanged

What happened

Merck has secured European Commission approval for ENFLONSIA to prevent RSV lower respiratory tract disease in infants, marking a regulatory win for its infectious disease portfolio. This approval aligns with Merck's broader strategy to diversify revenue streams ahead of Keytruda's loss of exclusivity, as highlighted in the DeepValue report. However, the report emphasizes that Merck's critical near-term bridges rely on WINREVAIR's commercial durability and KEYTRUDA QLEX adoption, not new approvals like ENFLONSIA which lack immediate scale. Investors must recognize that ENFLONSIA's contribution will be incremental compared to the multi-billion dollar acquisition charges and execution milestones driving the stock's valuation. Thus, while the approval supports portfolio breadth, it does not mitigate the earnings-quality risks or bridge credibility concerns central to the current investment thesis.

Implication

The approval adds a new product to Merck's portfolio, potentially enhancing long-term growth in infectious diseases, but it is unlikely to materially impact 2026-2027 financials given the small target population and competitive RSV market. Investors should view this as a positive but peripheral development, as the DeepValue report underscores that Merck's stock performance hinges on avoiding additional acquisition charges beyond the disclosed $14.8 billion and hitting WINREVAIR metrics of over 8,000 starts. ENFLONSIA does not address the earnings-quality deterioration from large non-GAAP adjustments, which caps valuation multiples until cleaner results emerge. Moreover, the approval fails to accelerate the Keytruda defense timeline or reduce dependence on the uncertain M&A-driven bridge strategy. Consequently, the WAIT rating remains appropriate, with investors advised to monitor upcoming Terns deal closure and WINREVAIR updates for more significant signals.

Thesis delta

No material shift in the investment thesis; ENFLONSIA approval is a minor positive that does not change the requirement for evidence on WINREVAIR durability and KEYTRUDA QLEX adoption by Q3 2026. The core risks—charge creep and bridge execution—remain unaltered, reinforcing the need to wait for clearer operational milestones before considering an entry.